{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.2","upperLimit":"98.7","value":"94.9"},{"groupId":"OG001","lowerLimit":"79.2","upperLimit":"97.6","value":"92.8"},{"groupId":"OG002","lowerLimit":"82.5","upperLimit":"98.8","value":"95.3"},{"groupId":"OG003","lowerLimit":"82.8","upperLimit":"99.6","value":"97.4"}]}],"title":"24 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.9","upperLimit":"96.0","value":"89.7"},{"groupId":"OG001","lowerLimit":"79.2","upperLimit":"97.6","value":"92.8"},{"groupId":"OG002","lowerLimit":"76.4","upperLimit":"96.3","value":"90.4"},{"groupId":"OG003","lowerLimit":"80.6","upperLimit":"98.7","value":"94.7"}]}],"title":"36 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.6","upperLimit":"92.7","value":"84.5"},{"groupId":"OG001","lowerLimit":"72.4","upperLimit":"94.6","value":"87.5"},{"groupId":"OG002","lowerLimit":"69.7","upperLimit":"93.0","value":"85.1"},{"groupId":"OG003","lowerLimit":"71.2","upperLimit":"94.3","value":"86.8"}]}],"title":"48 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.6","upperLimit":"90.9","value":"81.8"},{"groupId":"OG001","lowerLimit":"72.4","upperLimit":"94.6","value":"87.5"},{"groupId":"OG002","lowerLimit":"66.6","upperLimit":"91.2","value":"82.4"},{"groupId":"OG003","lowerLimit":"64.3","upperLimit":"90.5","value":"81.1"}]}],"title":"60 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.3","upperLimit":"88.9","value":"79.0"},{"groupId":"OG001","lowerLimit":"72.4","upperLimit":"94.6","value":"87.5"},{"groupId":"OG002","lowerLimit":"63.2","upperLimit":"89.3","value":"79.6"},{"groupId":"OG003","lowerLimit":"64.3","upperLimit":"90.5","value":"81.1"}]}],"title":"72 Months (n=43,44,44,42)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.2","upperLimit":"82.2","value":"70.0"},{"groupId":"OG001","lowerLimit":"72.4","upperLimit":"94.6","value":"87.5"},{"groupId":"OG002","lowerLimit":"59.7","upperLimit":"87.2","value":"76.6"},{"groupId":"OG003","lowerLimit":"60.1","upperLimit":"88.2","value":"77.7"}]}],"title":"84 Months (n=43,44,44,42)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"42"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization until death. Survival data were collected for up to 5 years on participants who had discontinued dasatinib treatment. Participants who did not die or who were lost to follow-up were censored on the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 100 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.\n\nAfter the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG000","title":"100mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.","id":"OG001","title":"140mg QD"},{"description":"Participants received 50 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.","id":"OG002","title":"50mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing.","id":"OG003","title":"70mg BID"}],"paramType":"NUMBER","populationDescription":"All randomized imatinib-intolerant participants were summarized.","reportingStatus":"POSTED","timeFrame":"24, 36, 48, 60, 72, and 84 months","title":"Percent of Imatinib Intolerant Participants With Overall Survival After 24, 36, 48, 60, 72, and 84 Months of Follow-up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}